Migraine
Conditions
Brief summary
Olanzapine (o-lan-zah-peen) is a medication that has been approved by the Food and Drug Administration (FDA) for the treatment of patients with schizophrenia and/ or bipolar disorder. The trade name for this drug is Zyprexa®. Olanzapine has not been approved by the FDA for the prevention of migraine and is experimental for the purposes of this research study. The Jefferson Headache Center at Thomas Jefferson University has developed this clinical study to evaluate the safety and effectiveness of Olanzapine in preventing migraine headaches.
Interventions
DRUGOlanzapine during first intervention period and placebo during second intervention period
Olanzapine (5-10 mg) daily during first intervention period, then placebo(matching)druing second intervention period (after a washout period)
DRUGPlacebo during first intervention period, then olanzapine during second intervention period
Placebo (matching) during first intervention period, then olanzapine (5-10 mg. daily) during the second intervention period (after a washout phase).
Sponsors
Eli Lilly and Company
Thomas Jefferson University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Subjects who are male or female between the ages of 18 and 65, inclusive * Subjects who have a history of migraine with or without aura as defined by IHS criteria, for at least one year prior to screening * Subjects who experience between 3 and 10 migraine attacks per month, for the three months preceding screening * Subjects who have no more than 15 headache days per month * Subjects who have been on a stable dose (no clinically significant changes) of all daily medications, for any indication, from 28 days prior to screening through the duration of the trial. * Women who are using, or agree to use for the duration of the study, a medically acceptable form of contraception (as determined by the investigator), if female of childbearing potential. * Subjects who are able to understand and comply with all study requirements * Subjects who provide written informed consent prior to any study procedures being performed.
Exclusion criteria
* Women who are pregnant or lactating * Subjects with an abnormal ECG that, in the investigators opinion, would expose them to increased risk of adverse events or interfere with study drug and/or analysis of efficacy/tolerability (subjects with QTC interval greater than 450ms will be excluded) * Subjects currently taking, or have taken within the thirty days prior to screening, any neuroleptics \> 1 day per week (such as Geodon, Zyprexa, Compazine, Phenergan, Seroquel and other drugs in the same class) * Subjects currently taking or have taken within 4-weeks prior to screening any medication for the prevention of migraine * Subjects who have failed more than two adequate trials of migraine prophylaxis, as determined by investigator * Subjects who experience significant orthostatic hypotension, as determined by the investigator * Subjects who, in the investigators opinion, have a history or have evidence of a medical condition that would expose them to an increased risk of a significant adverse event or would interfere with the assessments of efficacy and tolerability during this trial * Subjects who, in the investigators opinion, have a history or have evidence of a psychiatric condition that would expose them to an increased risk of a significant adverse event or would interfere with the assessments of efficacy and tolerability during this trial. * Subjects who have participated in an investigational drug trial in the 30 days prior to the screening visit
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Difference in Migraine Headache Periods During the Active Treatment Period as Compared to the Placebo Treatment Period, Per Subject. | 84 day period on placebo compared to 84 day period on olanzapine | Definition of migraine headache period: One migraine period is defined as a 24-hour period starting at the time of onset of the migraine headache, during which the migraine headache is present\*. Definition of time frames: First treatment period: Day 1 to 84. Second treatment period: day 113-196. Washout phase is day 85-112. |
Secondary
| Measure | Time frame |
|---|---|
| Reduction of Migraine Attack Frequency During Each 28-day Interval of the Active Treatment Period as Compared to Each 28-day Interval of the Placebo Treatment Period, Per Subject. Individual Migraine Attacks Are Separated by 48-hours Pain Free Time. A | each 28 day interval of active treatment c ompared to placebo |
| Reduction in Days Using an Acute Headache Treatment During the Active Treatment Period as Compared to the Placebo Treatment Period, Per Subject. | 84 day period on olanzapine compared to 84 day period on placebo |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Olanzapine First, Then Placeb Olanzapine (5-10 mg daily) during first intervention period and matching placebo in second intervention period (after washout period) | 3 |
| Placebo First, Then Olanzapine Matching placebo during first intervention period, then olanzapine (5-10 mg. daily) during second intervention period (after washout period). | 0 |
| Total | 3 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| First Intervention | Adverse Event | 2 | 0 |
Baseline characteristics
| Characteristic | Total | Olanzapine First, Then Placeb |
|---|---|---|
| Age Categorical <=18 years | 0 participants | 0 participants |
| Age Categorical >=65 years | 0 participants | 0 participants |
| Age Categorical Between 18 and 65 years | 3 participants | 3 participants |
| Age Continuous | 50 years STANDARD_DEVIATION 3 | 50 years STANDARD_DEVIATION 3 |
| Gender Female | 2 participants | 2 participants |
| Gender Male | 1 participants | 1 participants |
| Region of Enrollment United States | 3 participants | 3 participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 2 / 3 | 0 / 0 |
| serious Total, serious adverse events | 0 / 3 | 0 / 0 |
Outcome results
Primary
Difference in Migraine Headache Periods During the Active Treatment Period as Compared to the Placebo Treatment Period, Per Subject.
Definition of migraine headache period: One migraine period is defined as a 24-hour period starting at the time of onset of the migraine headache, during which the migraine headache is present\*. Definition of time frames: First treatment period: Day 1 to 84. Second treatment period: day 113-196. Washout phase is day 85-112.
Time frame: 84 day period on placebo compared to 84 day period on olanzapine
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Olanzapine First, Then Placeb | Difference in Migraine Headache Periods During the Active Treatment Period as Compared to the Placebo Treatment Period, Per Subject. | 0 headache periods | Standard Deviation 0 |
Secondary
Reduction in Days Using an Acute Headache Treatment During the Active Treatment Period as Compared to the Placebo Treatment Period, Per Subject.
Time frame: 84 day period on olanzapine compared to 84 day period on placebo
Secondary
Reduction of Migraine Attack Frequency During Each 28-day Interval of the Active Treatment Period as Compared to Each 28-day Interval of the Placebo Treatment Period, Per Subject. Individual Migraine Attacks Are Separated by 48-hours Pain Free Time. A
Time frame: each 28 day interval of active treatment c ompared to placebo